IL142703A0 - New crystalline form of omeprazole - Google Patents

New crystalline form of omeprazole

Info

Publication number
IL142703A0
IL142703A0 IL14270398A IL14270398A IL142703A0 IL 142703 A0 IL142703 A0 IL 142703A0 IL 14270398 A IL14270398 A IL 14270398A IL 14270398 A IL14270398 A IL 14270398A IL 142703 A0 IL142703 A0 IL 142703A0
Authority
IL
Israel
Prior art keywords
methoxy
crystalline form
omeprazole
methylüsulfinylü
benzimidazole
Prior art date
Application number
IL14270398A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27543202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL142703(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL142703A0 publication Critical patent/IL142703A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14270398A 1998-11-10 1998-11-10 New crystalline form of omeprazole IL142703A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/SE1998/002028 WO1999008500A2 (fr) 1998-11-10 1998-11-10 Nouvelle forme cristalline d'omeprazole
BR9816067-2A BR9816067A (pt) 1998-11-10 1998-11-10 Forma a de omeprazol, omeprazol, processo para a preparação da forma a de omeprazol, formulação farmacêutica, uso de omeprazol, e, método de tratamento de distúrbios gastrointestinais.
CA002363810A CA2363810A1 (fr) 1998-11-10 1998-11-10 Nouvelle forme d'omeprazole
DE29823393U DE29823393U1 (de) 1998-11-10 1998-11-10 Neue kristalline Form von Omeprazol
EP98957255A EP0969819B1 (fr) 1998-11-10 1998-11-10 Nouvelle forme cristalline d'omeprazole
US10/076,225 US20020156284A1 (en) 1998-11-10 2002-02-13 Crystalline form of omeprazole

Publications (1)

Publication Number Publication Date
IL142703A0 true IL142703A0 (en) 2002-03-10

Family

ID=27543202

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14270398A IL142703A0 (en) 1998-11-10 1998-11-10 New crystalline form of omeprazole

Country Status (34)

Country Link
US (3) US6150380A (fr)
EP (2) EP0969819B1 (fr)
JP (1) JP3457945B2 (fr)
CN (1) CN1347413A (fr)
AT (1) ATE233755T1 (fr)
AU (1) AU756434B2 (fr)
BR (1) BR9816067A (fr)
CA (2) CA2363810A1 (fr)
CZ (1) CZ301635B6 (fr)
DE (3) DE969819T1 (fr)
DK (2) DK0969819T3 (fr)
DZ (1) DZ2669A1 (fr)
EE (1) EE04279B1 (fr)
ES (1) ES2139559T3 (fr)
FI (1) FI3873U1 (fr)
GR (1) GR990300034T1 (fr)
HK (1) HK1024242A1 (fr)
HR (1) HRP20010281B1 (fr)
HU (1) HUP0104379A3 (fr)
IL (1) IL142703A0 (fr)
IS (1) IS2025B (fr)
MA (1) MA26574A1 (fr)
NO (1) NO320014B1 (fr)
NZ (1) NZ511377A (fr)
PL (1) PL190870B1 (fr)
PT (1) PT969819E (fr)
RU (1) RU2207339C2 (fr)
SI (1) SI0969819T1 (fr)
SK (1) SK286562B6 (fr)
TR (1) TR200101282T2 (fr)
TW (1) TW533203B (fr)
UA (1) UA72748C2 (fr)
WO (1) WO1999008500A2 (fr)
ZA (1) ZA9811174B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SI20019A (sl) 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6750064B2 (en) * 2000-12-28 2004-06-15 S.S.C.I. Inc. Methods of screening for possible solid forms
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
US7855082B1 (en) 2001-10-31 2010-12-21 Astrazeneca Ab Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole
US7678816B2 (en) 2003-02-05 2010-03-16 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
US20040235904A1 (en) * 2003-03-12 2004-11-25 Nina Finkelstein Crystalline and amorphous solids of pantoprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2007510136A (ja) * 2003-10-06 2007-04-19 ソルヴィーアス　アクチェンゲゼルシャフト 分子状固体の結晶形態を並行検出する方法
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
EP1907375B1 (fr) * 2005-06-08 2013-07-24 LEK Pharmaceuticals d.d. Solvate cristallin de sodium d'omeprazole
EP1904064A4 (fr) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr Omeprazole de forme b
CA2624179A1 (fr) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Inhibiteurs deuteries d'atpase h+,k+ gastrique ayant des proprietes therapeutiques renforcees
CA2665226C (fr) 2006-10-05 2014-05-13 Santarus, Inc. Nouvelles formulations pour une liberation immediate d'inhibiteurs de pompe a protons et procedes d'utilisation de ces formulations
EP2486910A3 (fr) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Appareil comprenant plusieurs chambres et une tête de distribution
EP2114919A2 (fr) 2007-01-31 2009-11-11 Krka Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation d'oméprazole optiquement pur
US8018588B2 (en) * 2007-06-06 2011-09-13 Aptuit, Inc. Sample holder and sample preparation device
US20090010388A1 (en) * 2007-06-06 2009-01-08 Stahly Barbara C Microplate and methods of using the same
US20090104236A1 (en) * 2007-10-18 2009-04-23 Pharmaceutics International, Inc. Pharmaceutical solid hybrids
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (fr) * 2008-05-09 2009-11-12 Aptapharma, Inc. Pastilles multicouches inhibant la pompe à protons
WO2010134099A1 (fr) 2009-05-21 2010-11-25 Cadila Healthcare Limited Procédé de préparation dans un récipient unique d'oméprazole
BR112012010525A2 (pt) * 2009-11-03 2015-09-29 Glaxo Group Ltd novos processos
GB201001075D0 (en) 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
RU2501549C1 (ru) 2012-08-30 2013-12-20 Авва Девелопмент Лтд Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
WO2024075017A1 (fr) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition de calcification de valve aortique

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
ES2078447T3 (es) 1990-06-15 1995-12-16 Merck & Co Inc Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
WO1995018612A1 (fr) * 1994-01-05 1995-07-13 Aktiebolaget Astra Procede de traitement du psoriasis par omeprazole ou autres composes apparentes
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9704183D0 (sv) 1997-11-14 1997-11-14 Astra Ab New process

Also Published As

Publication number Publication date
DK0969819T3 (da) 2003-05-19
CA2363810A1 (fr) 1999-02-25
EE04279B1 (et) 2004-04-15
DE969819T1 (de) 2000-04-06
JP3457945B2 (ja) 2003-10-20
CA2284470C (fr) 2002-02-26
IS5935A (is) 2001-05-07
DK199900074U1 (da) 2000-02-10
WO1999008500A3 (fr) 1999-07-29
MA26574A1 (fr) 2004-12-20
DE29823393U1 (de) 1999-05-27
JP2001522780A (ja) 2001-11-20
GR990300034T1 (en) 2000-07-31
EE200100248A (et) 2002-10-15
US6384059B1 (en) 2002-05-07
DZ2669A1 (fr) 2003-03-22
ES2139559T3 (es) 2003-10-01
PL190870B1 (pl) 2006-02-28
PL348247A1 (en) 2002-05-20
SI0969819T1 (en) 2003-06-30
HRP20010281B1 (en) 2004-04-30
HUP0104379A2 (hu) 2002-04-29
AU756434B2 (en) 2003-01-16
AU1355199A (en) 1999-03-08
DE69811868D1 (de) 2003-04-10
HK1024242A1 (en) 2000-10-05
PT969819E (pt) 2003-06-30
CZ301635B6 (cs) 2010-05-12
FIU980578U0 (fi) 1998-12-21
ATE233755T1 (de) 2003-03-15
ES2139559T1 (es) 2000-02-16
EP1221314A1 (fr) 2002-07-10
CZ20011611A3 (cs) 2002-01-16
TR200101282T2 (tr) 2001-11-21
TW533203B (en) 2003-05-21
ZA9811174B (en) 2000-06-07
NO20012286D0 (no) 2001-05-09
US6150380A (en) 2000-11-21
NO20012286L (no) 2001-07-03
HUP0104379A3 (en) 2003-01-28
UA72748C2 (en) 2005-04-15
HRP20010281A2 (en) 2002-06-30
CA2284470A1 (fr) 1999-02-25
DE69811868T2 (de) 2004-03-04
IS2025B (is) 2005-08-15
FI3873U1 (fi) 1999-03-22
NZ511377A (en) 2003-04-29
NO320014B1 (no) 2005-10-10
CN1347413A (zh) 2002-05-01
SK286562B6 (sk) 2009-01-07
RU2207339C2 (ru) 2003-06-27
BR9816067A (pt) 2001-08-07
WO1999008500A2 (fr) 1999-02-25
SK5452001A3 (en) 2001-11-06
EP0969819A2 (fr) 2000-01-12
EP0969819B1 (fr) 2003-03-05
US20020156284A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
GR990300034T1 (en) New crystalline form of omeprazole
SE9702483D0 (sv) New compound
CA2357744A1 (fr) Sel de potassium, de (s)-omeprazole
CA2290963A1 (fr) Trihydrate de magnesium s-omeprazole
WO2002017358A3 (fr) Fractions heteroaryle substituees par quinuclidine destinees au traitement de maladies
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
MY118724A (en) New crystalline form of omeprazole
YU32301A (sh) Novi kristalni oblik omeprazola
MXPA05009183A (es) Polimorfos de s-omeprazol.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed